BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/9/2022 12:48:14 PM | Browse: 349 | Download: 719
 |
Received |
|
2022-03-19 20:52 |
|
Peer-Review Started |
|
2022-03-19 20:55 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-05-12 03:21 |
|
Revised |
|
2022-05-19 22:36 |
|
Second Decision |
|
2022-08-09 02:55 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-08-10 04:27 |
|
Articles in Press |
|
2022-08-10 04:27 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-08-26 01:39 |
|
Publish the Manuscript Online |
|
2022-09-09 12:48 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Guillermo Valenzuela, Mauricio Burotto, Katherine Marcelain and Jaime González-Montero |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Agencia Nacional de Investigación y Desarrollo de Chile, Fondo Nacional de Investigación en Salud (FONIS) |
SA20I0059 |
|
| Corresponding Author |
Jaime González-Montero, MD, PhD, Assistant Professor, Department of Basic and Clinical Oncology, University of Chile, Independencia 1027, Casilla 70058, Santiago 8380453, Chile. jagonzalez@ug.uchile.cl |
| Key Words |
Colorectal neoplasms; Precision medicine; Liquid biopsy; Cetuximab; Panitumumab |
| Core Tip |
Contemporary management of metastatic colorectal cancer patients with wild type KRAS includes the use of anti-epidermal growth factor receptor (EGFR) agents, such as cetuximab or panitumumab, as first-line treatment. However, a significant number of patients receiving this treatment show disease progression. Some of the relapses could be explained by the presence of acquired resistance mutations in KRAS. Liquid biopsy of circulating tumor cells or circulating cell-free DNA is expected to improve the management of patients undergoing anti-EGFR therapy. |
| Publish Date |
2022-09-09 12:48 |
| Citation |
Valenzuela G, Burotto M, Marcelain K, González-Montero J. Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2022; 14(9): 1654-1664 |
| URL |
https://www.wjgnet.com/1948-5204/full/v14/i9/1654.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v14.i9.1654 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
